Etiology and Significance of Thrombocytopenia in Critically Ill Patients

Critical Care Clinics

Volumn 28, Issue 3, 2012, Pages 399-411

  Parker, Robert I ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Critically ill; Heparin induced thrombocytopenia; Intensive care unit; Platelets; Thrombocytopenia

Indexed keywords

ABCIXIMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FC RECEPTOR; FRESH FROZEN PLASMA; HEPARIN; IMMUNOGLOBULIN G; RHESUS D ANTIBODY; TICLOPIDINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AUTOIMMUNE THROMBOCYTOPENIA; BRAIN HEMORRHAGE; CRITICALLY ILL PATIENT; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EXPOSURE; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL; HEMOLYTIC UREMIC SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE MEDIATED INJURY; INTENSIVE CARE UNIT; PLASMAPHERESIS; POSTTRANSFUSION PURPURA; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PURPURA; REVIEW; RISK FACTOR; SEPSIS; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTICOAGULANTS; CRITICAL CARE; CRITICAL ILLNESS; HEPARIN; HUMANS; INTENSIVE CARE UNITS; PROGNOSIS; RISK FACTORS; THROMBOCYTOPENIA;

EID: 84862516883     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2012.04.007     Document Type: Review

References (72)

1. Priziola J.L., Smythe M.A., Dager W.E. Drug-induced thrombocytopenia in critically ill patients. Crit Care Med 2010, 38(6 Suppl):S145-S154.
2. Hanes S.D., Quarled D.A., Boucher B.A. Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother 1997, 31:285-289.
3. Cawley M.J., Wittbrodt E.T., Boyce E.G., et al. Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy 1999, 19:108-113.
4. Strauss R., Wehler M., Mehler K., et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements and outcome. Crit Care Med 2002, 30:1765-1771.
5. Hui P., Cook D.J., Lim W., et al. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest 2011, 139:271-278.
6. Wazny L.D., Ariano R.E. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000, 20:292-307.
7. Greinacher A., Selleng K. Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program 2010, 2010:135-143.
8. Bonfiglio M.F., Traeger S.M., Kier K.L., et al. Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients. Ann Pharmacother 1995, 29:835-842.
9. Shalansky S.J., Verma A.K., Levine M., et al. Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy 2002, 22:803-813.
10. Sharma B., Sharma M., Majumder M., et al. Thrombocytopenia in septic shock patients-a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care 2007, 35:874-880.
11. Vicente Rull J.R., Loza Aguirre J., de la Puerta E., et al. Thrombocytopenia induced by pulmonary artery flotation catheters: a prospective study. Intensive Care Med 1984, 10:29-31.
12. Vonderheide R.H., Thadhani R., Kuter D.J. Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med 1998, 105:27-32.
13. Vanderschueren S., De Weerdt A., Malbrain M., et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000, 28:1871-1876.
14. Akca S., Haji-Michael P., de Mendonca A., et al. Time course of platelet counts in critically ill patients. Crit Care Med 2002, 30:753-756.
15. Morerau D., Timsit J.F., Vesin A., et al. Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. Chest 2007, 131:1735-1741.
16. Krishnan J., Morrison W., Simone S., et al. Implications of thrombocytopenia and platelet course on pediatric intensive care unit outcomes. Pediatr Crit Care Med 2008, 9:502-505.
17. Nydam T.L., Kashuk J.L., Moore E.E., et al. Refractory postinjury thrombocytopenia is associated with multiple organ failure and adverse outcomes. J Trauma 2011, 70:401-406.
18. Masrouki S., Mebazaa M.S., Mestiri T., et al. Risk factors of mortality in critically ill patients with thrombocytopenia. Ann Fr Anesth Reanim 2004, 23:783-787.
19. Vandijck D.M., Blot S.I., De Waele J.J., et al. Thrombocytopenia and outcome in critically ill patients with bloodstream infection. Heart Lung 2010, 39:21-26.
20. Olmez I., Zafar M., Shahid M., et al. Analysis of significant decrease in platelet count and thrombocytopenia, graded according to NCI-CTC, as prognostic risk markers for mortality and morbidity. J Pediatr Hematol Oncol 2011, 33:585-588.
21. Von Lindern J.S., van den Bruele T., Lopriore E., et al. Thrombocytopenia in neonates and the risk of intraventricular hemorrhage: a retrospective cohort study. BMC Pediatr 2011, 11:16.
22. Warkentin T.E., Aird W.C., Rand J.H. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2003, 2003:497-519.
23. Katz J.N., Kolappa K.P., Becker R.C. Beyond thrombosis: the versatile platelet in critical illness. Chest 2011, 139:658-668.
24. Poncz M. Mechanistic basis of heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg 2005, 17:73-79.
25. Warkentin T.E. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin 2011, 27:805-823.
26. Davidson S.J., Wadham P., Rogers L., et al. Endothelial cell damage in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 2007, 18:317-320.
27. Greinacher A., Farner B., Kroll H., et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Throb Haemost 2005, 94:132-135.
28. Selleng K., Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007, 35:1165-1176.
29. Warkentin T.E., Greinacher A., Koster A., et al. Treatment and prevention of heparin-induced thrombocytopenia; 8th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008, 133(6 Suppl):340S-380S. American College of Chest Physicians.
30. Kato S., Takahashi K., Ayabe K., et al. Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients. Br J Haematol 2011, 154:373-377.
31. Lo G.K., Juhl D., Warkentin T.E., et al. Evaluation of pretest score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb haemost 2006, 4:759-765.
32. Crowther M.A., Cook D.J., Albert M., et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 2010, 25:287-293. The Canadian Critical Care Trials Group.
33. Cuker A., Arepally G., Crowther M.A., et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010, 8:2642-2650.
34. Verma A.K., Levine M., Shalansky S.J., et al. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003, 23:745-753.
35. Juhl D., Eichler P., Lubenow N., et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006, 76:420-426.
36. Greinacher A., Juhl D., Strobel U., et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007, 5:1666-1673.
37. Warkentin T.E., Sheppard J.L., Moore J.C., et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thormb Haemost 2008, 6:1304-1312.
38. Ruf K.M., Bensadoun E.S., Davis G.A., et al. A clinical-laboratory algorithm incorporating optical density value to predict heparin-induced thrombocytopenia. Thromb Haemost 2011, 105:553-559.
39. Baroletti S., Hurwitz S., Conti N.A., et al. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med 2012, 125:44-49.
40. Pouplard C., Leroux D., Regina S., et al. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010, 103:145-150.
41. Bakchoul T., Giptner A., Bein G., et al. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 2011, 127:345-348.
42. Morel-Kopp M.C., Tan C.W., Brighton T.A., et al. Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT. Results of a large Australian study. Thromb Haemost 2012, 107(3):575-583. ASTH Clinical Trials Group.
43. Prechel M.M., Escalante V., Drenth A.F., et al. A colorimetric, metabolic dye reduction assay detects highly activated platelets: application in the diagnosis of heparin-induced thrombocytopenia. Platelets 2012, 23:69-80.
44. Warkentin T.E. Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2010, 24:755-775.
45. Hassell K. Heparin-induced thrombocytopenia: diagnosis and management. Thromb Res 2008, 123(Suppl 1):S16-S21.
46. Warkentin T.E., Pai M., Sheppard J.L., et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay; a 30-month, 16-patient case series. J Thromb Haemost 2011, 9:2389-2396.
47. Patrick A.R., Winkelmayer W.C., Avorn J., et al. Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis. Pharmacoeconomics 2007, 25:949-961.
48. Smythe M.A., Koerber J.M., Fitzgerald M., et al. The financial impact of heparin-induced thrombocytopenia. Chest 2008, 134:568-573.
49. Elalamy I., Le Gal G., Nachit-Ouinekh F., et al. Heparin-induced thrombocytopenia: an estimate of the average cost in the hospital setting in France. Clin Appl Thromb Hemost 2009, 15:428-434.
50. Nanwa N., Mittmann N., Knowles S., et al. The direct medical costs associated with suspected heparin-induced thrombocytopenia. Pharmacoeconomics 2011, 29:511-520.
51. Liebman H. Other immune thrombocytopenias. Semin Hematol 2007, 44(4 Suppl 5):S24-S34.
52. Cines D.B., Liebman H., Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009, 46(1 Suppl 2):S2-S14.
53. Lajus S., Clofent-Sanchez G., Jais C., et al. Thrombocytopenia after abciximab use results from different mechanisms. Thromb Haemost 2010, 103:651-661.
54. Nurden P., Clofent-Sanchez G., Jais C., et al. Delayed immunologic thrombocytopenia induced by abciximab. Thromb Haemost 2004, 92:820-828.
55. Gonzalez C.E., Pengetze Y.M. Post-transfusion purpura. Curr Hematol Rep 2005, 4:154-159.
56. Shtalrid M., Shvidel L., Vorst E., et al. Post-transfusion purpura: a challenging diagnosis. Isr Med Assoc J 2006, 8:672-674.
57. Loren A.W., Abrams C.S. Efficacy of HPA-1a (PLA1)-negative platelets in a patient with post-transfusion purpura. Am J Hematol 2004, 76:2258-2262.
58. Lubenow N., Eichler P., Albrecht D., et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia: report of four cases and review of literature. Thromb Res 2000, 100:115-125.
59. Kitchens C.S. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematology Am Soc Hematol Educ Program 2009, 240-246.
60. Ten Cate H. Thrombocytopenia: one of the markers of disseminated intravascular coagulation. Pathophysiol Haemost Thromb 2003, 33:413-416.
61. Chapman K., Seldon M., Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012, 38:47-54.
62. Medina P.J., Sipols, George J.N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001, 8:286-293.
63. Zakarija A., Kwaan H.C., Moake J.L., et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl 2009, 112:S20-S24.
64. Coppo P., Veyradier A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med 2012, [Epub ahead of print].
65. Clark W.F. Thrombotic microangiopathy: Current knowledge and outcomes with plasma exchange. Semin Dial 2012, [Epub ahead of print].
66. Goldwater P.N., Bettelheim K.A. Treatment of enterohemorrhagic E. coli (EHEC) infection and hemolytic uremic syndrome (HUS). BMC Med 2012, 10:12.
67. Ohanian M., Cable C., Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 2011, 3:5-12.
68. Tamary H., Alter B.P. Current diagnosis of inherited bone marrow failure syndromes. Pediatr Hematol Oncol 2007, 24:87-99.
69. Dokal I., Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Rev 2008, 22:141-153.
70. Tamary H., Nishri D., Yacobovich J., et al. Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure registry. Haematologica 2010, 95:1300-1307.
71. Keohane E.M. Acquired aplastic anemia. Clin Lab Sci 2004, 17:165-171.
72. Davies J.K., Guinan E.C. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 2007, 136:549-564.